You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms
SBC: NeuroSigma, Inc. Topic: 101DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly scalable microfluidic platform for enhanced neuron-cell culture
SBC: Xona Microfluidics, Inc. Topic: 101DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of PAR Pepducins for the Treatment of Atopic Dermatitis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NIAMSDESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Simultaneous Proportional and Independent sEMG Based Hand Wrist Prosthesis Control
SBC: LIBERATING TECHNOLOGIES INC Topic: NICHDDESCRIPTION provided by applicant Surface electromyogram sEMG controlled powered hand wrist prostheses are used by upper limb amputees to return partial upper limb function Conventional transradial prostheses can use surface EMG amplitudes from the residual forearm flexors and extensors to control hand closing and opening respectively Additional degrees of freedom DoFs e g wrist rota ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDHuman respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
T SS needle protein inhibitors for the treatment of P aeruginosa infection
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAIDPROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Intra procedure Deformable Ultrasound MRI Fusion for Prostate Biopsies
SBC: ZMK Medical Technologies, Inc. Topic: 102This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health